These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 2789166)

  • 1. Humoral and cellular immunological factors as possible markers of clinical relapse in HLA-typed Graves' patients followed with time.
    Di Mario U; Vitillo M; Perfetti R; Mancuso M; Morellini M; Cappellacci S; Pozzilli P; Andreani D
    Horm Metab Res; 1989 May; 21(5):267-71. PubMed ID: 2789166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative immunological differences between newly diagnosed Graves' disease patients and relapsed patients.
    Di Mario U; Cavatorta FP; Perfetti R; Pugliese G; Pozzilli P; Sutherland J; Vitillo M; Andreani D
    J Endocrinol Invest; 1988 Feb; 11(2):85-9. PubMed ID: 3258878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased activated T-lymphocytes and normal thyrotropin receptor antibody levels in Graves' disease in long-term remission.
    Peakman M; Hussain M; Cundy T; Vergani D
    J Clin Lab Immunol; 1989 Sep; 30(1):1-5. PubMed ID: 2577115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
    Schott M; Morgenthaler NG; Fritzen R; Feldkamp J; Willenberg HS; Scherbaum WA; Seissler J
    Horm Metab Res; 2004 Feb; 36(2):92-6. PubMed ID: 15002058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antithyrotropin receptor antibodies in a series of Basedow's disease].
    Vidal E; Antoine E; Nadalon S; Cevallos R; Bournaud E; Vandroux JC; Bordessoule D; Loustaud V; Weinbreck P; Liozon F
    Ann Med Interne (Paris); 1988; 139(5):331-5. PubMed ID: 2462393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunity in Graves' disease at diagnosis: correlation between activated T cells and humoral immune factors.
    Di Mario U; Scardellato A; Irvine WJ; Kennedy L; Kadlubowski M; Kennedy R; Cavatorta FP; Andreani D
    Acta Endocrinol (Copenh); 1986 Dec; 113(4):493-9. PubMed ID: 3491482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antibodies against TSH receptors (TRAb) as indicators in prognosing the effectiveness of Tiamazol therapy for Grave's Disease].
    Bojarska-Szmygin A; Ciechanek R
    Wiad Lek; 2003; 56(7-8):303-7. PubMed ID: 14969154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
    Rink T; Holle LH; Schroth HJ; Garth H
    Nuklearmedizin; 1998 May; 37(3):90-4. PubMed ID: 9604228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulation by methimazole therapy in Graves' disease: rapid changes in activation stage of circulating regulatory T cell subsets, B cells and NK cells.
    Karlsson FA; Tötterman TH
    Clin Exp Immunol; 1988 Nov; 74(2):258-63. PubMed ID: 2906281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graves' disease: evolution and prognosis after eight months of treatment with methimazole.
    Gauna AT; Guillén CE; Sartorio GC; Soto RJ
    Medicina (B Aires); 1992; 52(3):207-12. PubMed ID: 1364158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T lymphocyte subsets at various stages of hyperthyroid Graves' disease: effect of carbimazole treatment and relationship with thyroid-stimulating antibody levels or HLA status.
    Madec AM; Allannic H; Genetet N; Gueguen M; Genetet G; Fauchet R; Stefanutti A; Orgiazzi J
    J Clin Endocrinol Metab; 1986 Jan; 62(1):117-21. PubMed ID: 3484386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of outcome in Graves' disease after carbimazole treatment.
    Weetman AP; Ratanachaiyavong S; Middleton GW; Love W; John R; Owen GM; Darke C; Lazarus JH; Hall R; McGregor AM
    Q J Med; 1986 Apr; 59(228):409-19. PubMed ID: 2875484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activated T cells in Graves' disease before treatment.
    Kennedy R; Di Mario U; Pozzilli P; Guy K; Leonardi M; Sensi M; Andreani D
    Clin Exp Immunol; 1985 Feb; 59(2):377-82. PubMed ID: 3156702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thyrotropin receptor antibodies (TRAb) as a test of surgical treatment effectiveness in Graves-Basedow's diseases].
    Bojarska-Szmygin A; Ciechanek R; Jezierska B; Zaorska-Rajca J
    Pol Merkur Lekarski; 2002 Sep; 13(75):196-9. PubMed ID: 12474569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [TSH anti-receptor antibodies in Graves' disease].
    Sérgio MR; Godinho C; Guerra L; Agapito A; Fonseca F; Costa C
    Acta Med Port; 1996; 9(7-9):229-31. PubMed ID: 9005701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of smoking on the course of Graves' disease after withdrawal of antithyroid drugs.
    Quadbeck B; Roggenbuck U; Janssen OE; Hahn S; Mann K; Hoermann R;
    Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):406-11. PubMed ID: 17039420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in TSH receptor antibody levels (TRAb) as markers of effectiveness of various therapies in Graves-Basedow's disease.
    Bojarska-Szmygin A; Janicki K; Pietura R; Janicka L
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):248-53. PubMed ID: 15314994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of cellular immune responses to thyrocyte membrane antigens and specific immunoregulatory defects in autoimmune thyroid disease.
    O'Brien CJ; Macchia E; Cundy TF; Concetti R; McSorley CG; MacFarlane IG; Vento S; Eddleston AL
    J Clin Lab Immunol; 1990 Jul; 32(3):103-8. PubMed ID: 1966945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of remission after antithyroid drug treatment in Graves' disease.
    Young ET; Steel NR; Taylor JJ; Stephenson AM; Stratton A; Holcombe M; Kendall-Taylor P
    Q J Med; 1988 Feb; 66(250):175-89. PubMed ID: 2902655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.